Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW856553 in Neuropathic Pain from Lumbosacral Radiculopathy
NCT01110057Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2010
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of losmapimod in neuropathic pain (2 arms), sponsored by GSK. Primary endpoint: Change in average daily neuropathic pain score at 5 weeks. Started Jan 2010; status: completed.
02
Drugs
losmapimod
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT01110057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01110057.